In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Serum uromodulin predicts mortality independently from the presence of type 2 diabetes

Session Poster session 7

Speaker Christoph Saely

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : A Leiherer (Feldkirch,AT), A Muendlein (Feldkirch,AT), CH Saely (Triesen,LI), J Ebner (Feldkirch,AT), EM Brandtner (Feldkirch,AT), A Schuler (Feldkirch,AT), P Schwerzler (Triesen,LI), A Mader (Triesen,LI), P Fraunberger (Feldkirch,AT), H Drexel (Philadelphia,US)

A. Leiherer1 , A. Muendlein1 , C.H. Saely2 , J. Ebner1 , E.M. Brandtner1 , A. Schuler3 , P. Schwerzler2 , A. Mader2 , P. Fraunberger4 , H. Drexel5 , 1VIVIT Institute - Feldkirch - Austria , 2Private University of the Principality of Liechtenstein - Triesen - Liechtenstein , 3Academic Teaching Hospital, Department of Medicine and Cardiology - Feldkirch - Austria , 4Medical Central Laboratory - Feldkirch - Austria , 5Drexel University College of Medicine - Philadelphia - United States of America ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 1325

Introduction: Uromodulin is produced exclusively by the kidneys and present in urine and blood. Low serum uromodulin has recently been demonstrated to be associated with chronic kidney disease and type 2 diabetes (T2DM).

Purpose: The purpose of this study was to investigate whether serum uromodulin also is a useful predictor of mortality.

Methods: We measured uromodulin in a series of 529 patients who underwent coronary angiography for the evaluation of established or suspected stable CAD and prospectively recorded mortality during a follow-up of up to 8 years.

Results: Uromodulin significantly correlated with eGFR (r=0.242, p<0.001) and, inversely, with age (r=-0.208, p<0.001), fasting glucose (r=-0.161, p<0.001), C-reactive protein (CRP; r=-0.133, p=0.002) and proBNP (r=-0.164, p=0.002); it was significantly lower in patients with T2DM than in nondiabetic subjects (148±70 vs. 171±79; p=0.001). Prospectively, we recorded 95 deaths; mortality was significantly higher in patients with T2DM than in those who did not have diabetes (28.2 vs. 14.6%; p<0.001). Serum uromodulin proved protective for overall mortality in univariate analysis (HR=0.56 [95% CI 0.43–0.72]; p<0.001), and also after multivariate adjustment for standard risk factors including diabetes, eGFR, proBNP and presence of CAD as well (adj. HR=0.57 [95% CI 0.37–0.89]; p=0.014).

Conclusion: We conclude that serum uromodulin predicts mortality independently from kidney function and the presence of T2DM.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are